Pharmacogenetics of psychotropic drugs and genetic influences on adverse drug reactions

精神药物的药物遗传学及药物不良反应的遗传影响

• 批准号: 1964821
• 金额: --
• 依托单位: University College London
• 依托单位国家: 英国
• 项目类别: Studentship
• 财政年份: 2018
• 资助国家: 英国
• 起止时间: 2018 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=studentship-1964821
• 关键词: Pharmacogenetics; psychotropic; drugs; genetic; influences

I investigate the impact of genetic variation on adverse drug reactions to psychotropic medications, with a focus on the metabolic-side effects of psychotropic drugs and the genetics basis of sleep disturbance in depression. In addition to reviewing published literature, I have considered this research topic in four main ways. Chapter one is a systematic review and meta-analysis of the impact of CYP2D6 genetic variation on antipsychotic-induced hyperprolactinaemia, which is a relatively common but understudied adverse-drug reaction. Chapters two and three are based on data from UK Biobank, where I have conducted a hypothesis-driven analysis of known pharmacogenes and their association with two common adverse drug reactions: increased diabetes risk and sleep disturbance. In working on this project, two key limitations became apparent. Firstly, the hypothesis-driven or 'candidate-gene' approach may limit discovery of novel loci of pharmacogenetic importance. Secondly, the nature of my analysis of cross-sectional UK Biobank data makes it difficult to draw firm conclusions on the causal direction of any observations. Therefore, chapters four and five aim to address these limitations. Chapter four builds on my pharmacogenetic analysis of antidepressant-induced sleep disturbance via a genome-wide association study of self-reported sleep duration, with an analysis of the genetic correlation between sleep and depression, as well Mendelian randomisation analyses to consider the causal direction of these association. In chapter five, I describe the set-up of a clinical study to assess pharmacogenetic interventions in a psychiatric patient population. Although limited data is available for analysis due to a pause in recruitment during the COVID-19 pandemic, I describe scientific rationale for the study and outline the work conducted to set-up and gain ethical approvals for the study, as well as an adjacent project to draft clinical guidelines for the implementation of pharmacogenetic testing in the NHS.

我调查了遗传变异对精神药物不良反应的影响，重点是精神药物的代谢副作用和抑郁症睡眠障碍的遗传学基础。除了回顾已发表的文献外，我还从四个主要方面考虑了这个研究课题。第一章是CYP 2D 6基因变异对抗精神病药物引起的高泌乳素血症的影响的系统综述和荟萃分析，这是一种相对常见但研究不足的药物不良反应。第二章和第三章基于英国生物银行的数据，在那里我对已知的药物基因及其与两种常见药物不良反应的关系进行了假设驱动的分析：糖尿病风险增加和睡眠障碍。在这个项目的工作中，两个关键的限制变得明显。首先，假设驱动或“候选基因”的方法可能会限制发现新的基因座的药物遗传学的重要性。其次，我对英国生物银行横截面数据的分析性质使得很难对任何观察结果的因果方向得出确切的结论。因此，第四章和第五章旨在解决这些局限性。第四章建立在我的药物遗传学分析抗抑郁药引起的睡眠障碍通过全基因组关联研究自我报告的睡眠时间，与睡眠和抑郁症之间的遗传相关性的分析，以及孟德尔随机分析，考虑这些关联的因果方向。在第五章中，我描述了一项临床研究的建立，以评估药物遗传学干预精神病患者群体。尽管由于COVID-19大流行期间暂停招募，可用于分析的数据有限，但我描述了这项研究的科学原理，并概述了为建立和获得研究伦理批准而进行的工作，以及为在NHS中实施药物遗传学测试起草临床指南的相邻项目。